Open AccessNovel Complement Factor H mutation, a case report of atypical hemolytic uremic syndrome
Author(s) -
Rodrigo A. Sepúlveda,
Rodrigo Tagle,
Aquiles Jara
Publication year - 2017
Publication title -
case reports in internal medicine
Language(s) - English
Resource type - Journals
eISSN - 2332-7251
pISSN - 2332-7243
DOI - 10.5430/crim.v4n2p13
Subject(s) - atypical hemolytic uremic syndrome , eculizumab , microangiopathic hemolytic anemia , complement factor i , medicine , cd46 , complement factor b , complement system , alternative complement pathway , factor h , immunology , hemolytic anemia , thrombotic microangiopathy , antibody , disease , thrombotic thrombocytopenic purpura , platelet
Atypical hemolytic uremic syndrome (aHUS) is a rare but catastrophic disease. It is characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. When the aHUS is primary, the cause is due to mutations in proteins that regulate the alternative pathway of complement, such as Factor H, Factor I, Factor B, C3, Membrane Co-Factor Protein and Thrombomodulin. Usually primary aHUS is associated with other amplifiers complement factors. We present a case of aHUS in a 25-year-old female patient; she presented with malignant hypertension and severe renal failure. After a widespread study, the etiology of the aHUS was a mutation in the complement factor H, not previously described in the literature (p.Tyr1177His). After treatment with Eculizumab (C5 inhibitor monoclonal antibody), she recovered renal function with not hemodialysis requirements.